Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 5243
Gene Symbol: ABCB1
ABCB1
0.020 GeneticVariation phenotype BEFREE This study suggests that C3435T polymorphisms in the ABCB1 gene are strongly associated with a predisposition to depression development, the severity of depressive symptoms and the effectiveness of therapy with using different groups of antidepressant agents. 26664259 2015
Entrez Id: 5243
Gene Symbol: ABCB1
ABCB1
0.020 GeneticVariation phenotype BEFREE The ABCB1 genotypes of rs1922242 (P=0.0028) and rs1202184 (P=0.0021) showed significant association with the severity of depressive symptoms as assessed by the Hamilton Rating Scale for Depression adjusted with Hamilton Rating Scale for Anxiety. 20859246 2011
Entrez Id: 10058
Gene Symbol: ABCB6
ABCB6
0.010 AlteredExpression phenotype BEFREE The ABC-6 was moderately, but significantly, correlated with physical activity level (r=0.528; p=0.017), mobility (r=-0.520; p=0.027), balance (r=0.633; p=0.003), and depressive symptoms (r=-0.515; p=0.020) in the DM study groups (concurrent validity). 28268190 2017
Entrez Id: 10060
Gene Symbol: ABCC9
ABCC9
0.310 Biomarker phenotype PSYGENET There was also a significant association between a different ABCC9 gene variant (rs11046205) and depressive symptoms. 23780892 2013
Entrez Id: 10060
Gene Symbol: ABCC9
ABCC9
0.310 GeneticVariation phenotype BEFREE There was also a significant association between a different ABCC9 gene variant (rs11046205) and depressive symptoms. 23780892 2013
Entrez Id: 84836
Gene Symbol: ABHD14B
ABHD14B
0.010 Biomarker phenotype BEFREE In single mediator analyses, increases in self-kindness (CIB [-7.83, -1.93]), decreases in rumination (CIB [-5.05, -.31]), and increases in mindfulness (CIB [-6.58, -.82]) each mediated reductions in depressive symptoms from pre- to postintervention. 28230391 2017
Entrez Id: 27034
Gene Symbol: ACAD8
ACAD8
0.010 GeneticVariation phenotype BEFREE Research in pediatric IBD documents increased depression risk, with rates up to 25%, as well as worse adherence and treatment outcomes associated with depressive symptoms. 31568153 2020
Entrez Id: 84680
Gene Symbol: ACCS
ACCS
0.010 Biomarker phenotype BEFREE <b>Methods:</b> A total of 100 stroke survivors were recruited from five metropolitan hospitals and assessed at 3- and 12-months post-stroke using measures of activity participation (Activity Card Sort-Australia (ACS-Aus)) and depressive symptoms (Montgomery-Asberg Depression Rating Scale Structured Interview Guide (MADRS-SIGMA)). 29889570 2019
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.330 Biomarker phenotype PSYGENET Previous studies have revealed the association of the ACE gene insertion/deletion polymorphism with depressive disorder and its treatment response but not with the depressive symptoms in schizophrenia. 25694211 2015
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.330 Biomarker phenotype BEFREE Associations between self-reported depressive symptoms and exposure to angiotensin converting enzyme inhibitors or calcium channel blockers were not observed. 7553546 1995
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.330 Biomarker phenotype BEFREE A path model indicated that maternal depressive symptoms accounted for the relation between higher maternal ACE scores and children's depressive symptoms. 31005595 2019
Entrez Id: 1636
Gene Symbol: ACE
ACE
0.330 GeneticVariation phenotype BEFREE Previous studies have revealed the association of the ACE gene insertion/deletion polymorphism with depressive disorder and its treatment response but not with the depressive symptoms in schizophrenia. 25694211 2015
Entrez Id: 43
Gene Symbol: ACHE
ACHE
0.020 Biomarker phenotype BEFREE Acetylcholinesterase inhibitors and memantine are effective in the symptomatic treatment of Alzheimer's disease but current evidence does not support their use to treat depressive symptoms in dementia. 28074409 2017
Entrez Id: 43
Gene Symbol: ACHE
ACHE
0.020 Biomarker phenotype BEFREE Lower AChE activity (reflecting greater cholinesterase inhibitor exposure) was associated with higher depression symptoms (difference per SD decrease of AChE [β [95% CI:]]: 1.09 [0.02, 2.16]), was stronger among girls (β = 1.61) than boys (β = 0.69), and among younger (<14.38y, β = 1.61) vs. older children (β = 0.57). 31202795 2019
Entrez Id: 57007
Gene Symbol: ACKR3
ACKR3
0.010 Biomarker phenotype BEFREE Employing methylation-array technology, a total of 363,887 methylation sites across the genomes were investigated and several candidate CpG sites associated with depressive symptoms were identified, especially annotated to genes linked to a G-protein coupled receptor protein signaling pathway. 29305581 2018
Entrez Id: 11332
Gene Symbol: ACOT7
ACOT7
0.010 Biomarker phenotype BEFREE This study suggests that NP functioning is unrelated to changes in pain interference associated with ACT, and that those with relatively lower NP functioning may experience greater reductions in depressive symptoms and pain-related anxiety. 29496638 2018
Entrez Id: 55902
Gene Symbol: ACSS2
ACSS2
0.010 Biomarker phenotype BEFREE <b>Methods:</b> A total of 100 stroke survivors were recruited from five metropolitan hospitals and assessed at 3- and 12-months post-stroke using measures of activity participation (Activity Card Sort-Australia (ACS-Aus)) and depressive symptoms (Montgomery-Asberg Depression Rating Scale Structured Interview Guide (MADRS-SIGMA)). 29889570 2019
Entrez Id: 345651
Gene Symbol: ACTBL2
ACTBL2
0.010 Biomarker phenotype BEFREE This study suggests that NP functioning is unrelated to changes in pain interference associated with ACT, and that those with relatively lower NP functioning may experience greater reductions in depressive symptoms and pain-related anxiety. 29496638 2018
Entrez Id: 71
Gene Symbol: ACTG1
ACTG1
0.010 Biomarker phenotype BEFREE This study suggests that NP functioning is unrelated to changes in pain interference associated with ACT, and that those with relatively lower NP functioning may experience greater reductions in depressive symptoms and pain-related anxiety. 29496638 2018
Entrez Id: 72
Gene Symbol: ACTG2
ACTG2
0.010 Biomarker phenotype BEFREE This study suggests that NP functioning is unrelated to changes in pain interference associated with ACT, and that those with relatively lower NP functioning may experience greater reductions in depressive symptoms and pain-related anxiety. 29496638 2018
Entrez Id: 9509
Gene Symbol: ADAMTS2
ADAMTS2
0.010 Biomarker phenotype BEFREE In this well-characterised cohort (n = 404) from the relatively genetically homogeneous Northern Ireland population, we tested the hypothesis that genetic variants of apolipoprotein E influence the risk for depressive symptoms in AD patients using the Neuropsychiatric Inventory (NPI-D) to determine the presence of depressive symptoms during the dementing illness. 15627763 2005
Entrez Id: 103
Gene Symbol: ADAR
ADAR
0.010 GeneticVariation phenotype BEFREE The presence of depressive symptoms and alcohol use were the factors most strongly associated with an increased risk of DSH. 31018001 2019
Entrez Id: 9370
Gene Symbol: ADIPOQ
ADIPOQ
0.100 Biomarker phenotype BEFREE In T2D, there was additional evidence for associations of IL-18 and (inversely) adiponectin with depressive symptoms. 29520075 2018
Entrez Id: 9370
Gene Symbol: ADIPOQ
ADIPOQ
0.100 AlteredExpression phenotype BEFREE The level of adiponectin is associated with obsessive and compulsive symptoms and resistin with depressive symptoms, which indicates their potential contribution to the regulation of emotions and behaviours in AN. 30264643 2019
Entrez Id: 9370
Gene Symbol: ADIPOQ
ADIPOQ
0.100 Biomarker phenotype BEFREE In this investigation, fasting blood samples from 120 individuals with BD (75 euthymic and 45 with mild depressive symptoms) and 68 control subjects were taken and adiponectin and leptin concentrations were analysed. 30047831 2019